A novel cell penetrating peptide as vector for therapeutic cancer vaccine: a proof-of-concept

• Forschungsstelle: INNOSUISSE
• Projektnummer: 13070.1;6 PFLS-LS
• Projekttitel Englisch: A novel cell penetrating peptide as vector for therapeutic cancer vaccine: a proof-of-concept

Kurzbeschreibung (Englisch)

A novel cell penetrating peptide as vector for therapeutic cancer vaccine: a proof-of-concept

Kurzbeschreibung (Französisch)

A novel cell penetrating peptide as vector for therapeutic cancer vaccine: a proof-of-concept

Abstract (Englisch)

Seen as promising therapy, different therapeutic cancer vaccine approaches have been developed and evaluated to teach the killer cells of the immune system to specifically recognize and attack the tumor cells. Tumor specific killer cells were often described however, only occasionally correlating with tumor regression.It is in this context that we aim to develop an innovative proprietary 2nd generation cancer-vaccine platform, based on a new cell penetrating peptide fused to a protein to achieve multi-epitopic, multi-allelic and polyfunctional antitumor immunity.

Abstract (Französisch)

Seen as promising therapy, different therapeutic cancer vaccine approaches have been developed and evaluated to teach the killer cells of the immune system to specifically recognize and attack the tumor cells. Tumor specific killer cells were often described however, only occasionally correlating with tumor regression.It is in this context that we aim to develop an innovative proprietary 2nd generation cancer-vaccine platform, based on a new cell penetrating peptide fused to a protein to achieve multi-epitopic, multi-allelic and polyfunctional antitumor immunity.